Schizophrenia Spectrum: Timelines & Dopamine Pathways
The clock sets the diagnosis; dopamine pathways explain the symptoms
Psychotic Symptoms
Positive symptoms. These add abnormal experience. Delusions are fixed false beliefs held despite contrary evidence, most often persecutory or referential. Hallucinations in schizophrenia are usually auditory, typically voices that comment on or converse about the patient. Disorganized speech ranges from tangentiality and loose associations to word salad, and behavior may be grossly disorganized or catatonic.
Prominent visual, tactile, or olfactory hallucinations suggest a secondary cause: visual with delirium, hallucinogens, or Lewy body dementia; tactile (formication) with stimulants or alcohol withdrawal; olfactory with temporal lobe seizures. Hypnagogic and hypnopompic hallucinations are normal or point to narcolepsy.
Negative symptoms. These are deficits, the five A's: flat or blunted affect, alogia, avolition, anhedonia, and asociality. They cause most long-term disability, predict a poorer outcome, and respond poorly to antipsychotics. Cognitive impairment in attention, working memory, and executive function accompanies them. Antipsychotic-induced parkinsonism, depression, and understimulation can produce look-alike secondary negative symptoms.
Duration-Based Diagnoses
Schizophrenia criteria. At least two core symptoms (delusions, hallucinations, disorganized speech, disorganized or catatonic behavior, negative symptoms), one of which must be delusions, hallucinations, or disorganized speech, present for at least 1 month, within at least 6 months of continuous disturbance that includes prodromal or residual phases, with decline in work, relationships, or self-care. Substance-induced, medical, and mood causes must be excluded.
| Disorder | Duration | Distinguishing features |
|---|---|---|
| Brief psychotic disorder | 1 day to <1 month | Full return to baseline; often after a stressor or postpartum |
| Schizophreniform disorder | 1–6 months | Functional decline not required; about one-third recover, most others progress to schizophrenia or schizoaffective disorder |
| Schizophrenia | ≥6 months (≥1 month active) | Functional decline; prodromal and residual phases count |
| Schizoaffective disorder | Psychosis ≥2 weeks without mood episode | Major depressive or manic episodes present for most of the illness |
| Delusional disorder | ≥1 month | Erotomanic, grandiose, jealous, persecutory, or somatic delusions; functioning otherwise preserved |
If psychotic symptoms occur only during mood episodes, the diagnosis is major depressive or bipolar disorder with psychotic features, not schizoaffective disorder.
Delusional disorder. Patients rarely seek care and usually lack insight. In shared delusions (folie à deux), a dependent partner adopts the delusion of a dominant person, and separation often helps the secondary partner.
Dopamine Pathways and the NMDA Hypothesis
| Pathway | Projection | Clinical relevance |
|---|---|---|
| Mesolimbic | Ventral tegmental area → nucleus accumbens, limbic system | Excess dopamine → positive symptoms; the therapeutic target of D2 blockade |
| Mesocortical | VTA → prefrontal cortex (dorsolateral) | Deficient dopamine → negative and cognitive symptoms; D2 blockade may worsen them |
| Nigrostriatal | Substantia nigra → striatum | D2 blockade → extrapyramidal symptoms |
| Tuberoinfundibular | Hypothalamus → anterior pituitary | D2 blockade → hyperprolactinemia |
Side effects of D2 blockade. Nigrostriatal blockade, most marked with high-potency typicals such as haloperidol, causes acute dystonia (hours to days), akathisia (days to weeks), parkinsonism (weeks to months), and tardive dyskinesia (months to years). Dopamine from the tuberoinfundibular pathway tonically inhibits lactotrophs, so blockade causes hyperprolactinemia with galactorrhea, amenorrhea, gynecomastia, and sexual dysfunction; risperidone is the classic atypical culprit. Second-generation antipsychotics add 5-HT2A antagonism, which increases dopamine release in the prefrontal cortex and striatum and is one explanation for their lower EPS risk.
Glutamate hypothesis. Drugs that raise dopamine (amphetamine, cocaine, levodopa) mainly produce positive symptoms, whereas NMDA receptor antagonists (phencyclidine, ketamine) reproduce positive, negative, and cognitive symptoms. Underactive NMDA receptors on GABAergic interneurons are thought to disinhibit glutamate projections that dysregulate midbrain dopamine neurons.
Risk Factors, Brain Findings, and Prognosis
Epidemiology and risk. Lifetime prevalence is about 1%. Onset is typically in the late teens to early 20s in men and the late 20s in women. Genetic risk is strong (monozygotic concordance about 40–50%; 22q11.2 deletion), and environmental risks include adolescent cannabis use, urban birth and upbringing, migration, advanced paternal age, and prenatal infection, malnutrition, or obstetric complications.
Brain findings. Imaging shows enlarged lateral and third ventricles, cortical thinning, and smaller hippocampi. Microscopically there is reduced neuropil and fewer dendritic spines without gliosis, consistent with a neurodevelopmental disorder.
- Better prognosis: acute and later onset, female sex, clear precipitant, prominent positive or mood symptoms, good premorbid functioning.
- Worse prognosis: insidious early onset, male sex, prominent negative symptoms, poor premorbid functioning, family history of schizophrenia.
Exclude secondary psychosis before diagnosing a primary disorder: stimulants, PCP, cannabis, hallucinogens, corticosteroids, levodopa, alcohol withdrawal, delirium, temporal lobe epilepsy, brain tumors, SLE, HIV, neurosyphilis, Wilson and Huntington disease, and thyroid disease.